secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-09-29T11:22:07+00:00
Accession:  0001398733-26-000052
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aquestive Therapeutics elects Richard J. Daly to board, expanding directorships from seven to eight
--------------------------------------------------------------------------------

- Richard J. Daly elected as Class I director effective October 14, 2026, with term expiring at the 2028 Annual Meeting of Stockholders.
- Board size increased from seven to eight directors; seven of eight are independent under Nasdaq listing standards.
- Daly receives an initial award of 57,000 stock options under the 2018 Equity Incentive Plan, vesting in annual one-third increments.
- Option grant date is the second full trading day after the next quarterly or annual earnings release, with exercise price equal to that day's closing price.
- CEO Daniel Barber cited Daly's commercial leadership at AstraZeneca, Takeda and Catalyst as valuable for a potential Anaphylm launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/0001398733-26-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/aqst-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer